New long-term ambitions will be defined at later date, says Ambu CEO

Nothing will be revealed about new organic growth and operating margin goals until the medtech firm’s capital markets day in March, says Ambu CEO Britt Meelby Jensen.

Britt Meelby Jensen, CEO of Ambu | Photo: Zealand Pharma/PR

It is too early and market conditions are too uncertain to determine exactly when Ambu’s long-term expectations for organic growth will be met, Ambu CEO Britt Meelby Jensen tells MarketWire. Neither can an industry operating margin standard meaningfully be predicted or defined at this time.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs